Introduction {#section5-1753465816676222}
============

Emphysema is a debilitating chronic pulmonary disease \[[@bibr38-1753465816676222]\]. It is characterized by structural changes in lung parenchyma with consecutive reduction of gas exchange surface, loss of elastic recoil and dynamic hyperinflation leading to dyspnea, limited exercise capacity and reduced quality of life. In the advanced stages, it leads to respiratory failure: hypoxemia and eventually chronic hypercapnic respiratory failure (type 2 respiratory failure). Hyperinflation is a major component in the development of chronic hypercapnic respiratory failure as it is associated with an increased ventilatory workload, with key pathophysiological elements being the loss of elastic recoil as well as geometrical changes of diaphragm and thorax compromising the function of the diaphragmatic, intercostal and accessory muscles \[[@bibr27-1753465816676222]\].

The condition is incurable and therapeutic options are limited. In selected patients with severe emphysema, lung volume reduction may be considered \[[@bibr16-1753465816676222]\]. The original procedure, lung volume reduction surgery, has been shown to be beneficial and safe if performed in carefully and properly selected patients \[[@bibr11-1753465816676222]; [@bibr19-1753465816676222]; [@bibr10-1753465816676222]\]. Over the last decade, sophisticated interventional bronchoscopic procedures have been added to the repertoire of lung volume reduction. Procedures developed for bronchoscopic use included one-way valves \[[@bibr34-1753465816676222]\], airway bypass stents \[[@bibr6-1753465816676222]\], biological lung volume reduction \[[@bibr26-1753465816676222]\], bronchoscopic thermal vapor ablation \[[@bibr35-1753465816676222]\] and coils \[[@bibr13-1753465816676222]\].

Endoscopic lung volume reduction coil (LVRC) treatment was first introduced in 2010 \[[@bibr13-1753465816676222]\]. It is a treatment option not only for patients with heterogeneous emphysema but also for patients with homogeneous emphysema \[[@bibr15-1753465816676222]\] and is independent of the presence of collateral ventilation. Beneficial effects of LVRC treatment have been shown regarding pulmonary function, exercise capacity and quality of life \[[@bibr7-1753465816676222]; [@bibr15-1753465816676222]; [@bibr32-1753465816676222]; [@bibr33-1753465816676222]\]. LVRC treatment has also been shown to have a good safety profile \[[@bibr12-1753465816676222]; [@bibr31-1753465816676222]\].

Careful patient selection is mandatory before endoscopic lung volume reduction. In a recently published review, a partial pressure of carbon dioxide in arterial blood (PaCO~2~) \<50 mmHg has been listed among the prerequisites for endoscopic lung volume reduction \[[@bibr16-1753465816676222]\]. However, it can be hypothesized, that LVRC treatment, a procedure explicitly designed to target hyperinflation and thereby reducing ventilatory workload, may be especially beneficial in patients with chronic hypercapnic respiratory failure. We therefore conducted this retrospective analysis on LVRC treatment in patients with chronic hypercapnic respiratory failure. To our knowledge, this is the first analysis of the effectiveness and safety of LVRC treatment in patients with chronic hypercapnic respiratory failure published to date.

Materials and methods {#section6-1753465816676222}
=====================

Study design {#section7-1753465816676222}
------------

This was a retrospective observational trial conducted in the Department of Respiratory Medicine at the University Medical Center Hamburg-Eppendorf, Germany. Inclusion criteria were (1) bilateral LVRC treatment and (2) chronic hypercapnic respiratory failure due to emphysema. Chronic hypercapnic respiratory failure was defined as a PaCO~2~ \> 45 mmHg and normal pH at rest while in a clinically stable condition and despite optimal therapy for chronic obstructive pulmonary disease (COPD). The ethics committee of the Hamburg chamber of physicians waived the need for ethics approval and for the need to obtain consent for the collection, analysis, and publication of the retrospectively-obtained and anonymized data for this noninterventional study.

Data collection {#section8-1753465816676222}
---------------

The electronic endoscopic database (Endobase, version 12.0, Olympus, Tokyo, Japan) was searched for all cases of LVRC treatment specifying a time frame between 1 April 2012 and 30 September 2015. The electronic patient database including the electronic patient record (Soarian Clinicals, version 3.00 SP3, Cerner Health Services, USA) was then used to retrieve patient characteristics, procedural details and data collected during initial assessment and follow-up visits including the results of the assessments of pulmonary function and exercise capacity.

LVRC treatment {#section9-1753465816676222}
--------------

In our department, all patients with severe emphysema are thoroughly evaluated considering lung volume reduction surgery, different techniques of endoscopic lung volume reduction and lung transplantation. Criteria to indicate endoscopic lung volume reduction include the presence of emphysema, symptoms despite optimal medical therapy and pulmonary rehabilitation, severe or very severe airflow obstruction as defined by the global initiative for chronic obstructive lung disease (GOLD) definition, hyperinflation with, at the time of this study, a residual volume (RV) \>175% of predicted and the absence of excessive sputum or active infection. To select the appropriate technique, the distribution of emphysema, the degree of tissue destruction, the evaluation of interlobar collateral ventilation and comorbidities are taken into account, with homogeneous emphysema, the presence of collateral ventilation in patients with heterogeneous emphysema and tissue destruction \<75% being among the criteria in favor of LVRC treatment.

Prior to endoscopic lung volume reduction, patients are routinely screened for signs of right ventricular strain and pulmonary hypertension. Unless pulmonary hypertension has been previously diagnosed or excluded by right heart catheterization, screening includes echocardiography, the measurement of NT-proBNP levels as well as the evaluation of computed tomography scans for the presence of a pulmonary arterial diameter \>3 cm, a ratio of the right to left atrial diameter \>1, a ratio of the pulmonary arterial to the aortic diameter \>1 and reflux of intravenous contrast into the inferior vena cava. In cases where severe pulmonary hypertension, defined as a systolic pulmonary arterial pressure \>50 mmHg, has been diagnosed or is suspected, patients are excluded from endoscopic lung volume reduction.

LVRC treatment is performed bilaterally in two sequential procedures unless complications or contraindications arise or the patient opts for unilateral treatment only. The aim is to complete the second procedure 1--3 months after the first procedure. The targeted lobe and the sequence are selected according to the distribution of emphysema and the degree of tissue destruction, with the upper lobes being preferentially treated in patients with homogeneous emphysema \[[@bibr8-1753465816676222]; [@bibr15-1753465816676222]\].

Assessment of pulmonary function and exercise capacity {#section10-1753465816676222}
------------------------------------------------------

In our department, as a routine standard of care in patients with LVRC treatment, pulmonary function and exercise capacity are assessed in a standardized manner at baseline, between the first and second LVRC treatment and at each outpatient follow-up visit. Pulmonary function tests including spirometry, body plethysmography and carbon monoxide uptake as well as blood gas analyses are performed according to the American Thoracic Society and European Respiratory Society guidelines \[[@bibr25-1753465816676222]; [@bibr18-1753465816676222]; [@bibr40-1753465816676222]; [@bibr20-1753465816676222], [@bibr21-1753465816676222]\]. Exercise capacity is assessed using the 6-min walk test \[[@bibr14-1753465816676222]; [@bibr3-1753465816676222]\].

Adverse events {#section11-1753465816676222}
--------------

The electronic patient record was systematically reviewed for adverse events. As a routine standard of care, patients after LVRC treatment are questioned about changes in dyspnea and the occurrence of hemoptysis or chest pain on a daily basis during hospitalization and at each outpatient visit. Outpatient visits are routinely scheduled between the first and second treatment approximately 1 month after the first treatment as well as 3 months, 6 months and 12 months after the second treatment. Any complications encountered during the bronchoscopic procedure as well as pneumothoraces, respiratory infections, COPD exacerbations within 4 weeks of the procedure, pleuritic pain associated with the position of coils and hemoptysis occurring at any time during the follow-up period were considered adverse events.

Data analysis {#section12-1753465816676222}
-------------

Categorical variables are presented as absolute numbers and percentages. Continuous variables are presented as mean and standard deviation if normally distributed and as median and range if not normally distributed. Comparisons were performed using the Student's *t* test for metric data. A two-sided *p* value \<0.05 was considered significant. The software used for statistical analyses was SPSS version 21.0 (SPSS Inc., Chicago, IL, USA).

Results {#section13-1753465816676222}
=======

Case selection {#section14-1753465816676222}
--------------

Between 1 April 2012 and 30 September 2015 a total of 101 LVRC procedures were performed in 62 patients. Among these were 19 patients with chronic hypercapnic respiratory failure. LVRC treatment was performed only unilaterally in nine of these patients. Overall, 10 patients met inclusion criteria and were analyzed in this study. The process of case selection is shown in [Figure 1](#fig1-1753465816676222){ref-type="fig"}.

![Flow diagram illustrating the process of case selection.\
COPD, chronic obstructive pulmonary disease; LVRC, endoscopic lung volume reduction coil; PaCO~2~, partial pressure of carbon dioxide in arterial blood.](10.1177_1753465816676222-fig1){#fig1-1753465816676222}

Characteristics of patients at baseline {#section15-1753465816676222}
---------------------------------------

Of the 10 patients included in the study, 70% were female and 30% were male. Mean age was 64 ± 9 years. All patients were on optimal pharmacological therapy for their pulmonary disease. Additionally, all patients were on long-term oxygen therapy due to chronic hypoxemia and 70% were on intermittent noninvasive ventilation. Emphysema was homogeneous in 80% and heterogeneous in 20% of cases. All patients had very severe airflow obstruction as defined by the GOLD criteria. At baseline, mean forced expired volume in one second (FEV~1~) was 0.5 ± 0.1 l equal to 17 ± 5% of predicted. Mean RV was 6.1 ± 0.9 l equal to 280 ± 48% of predicted. Mean forced vital capacity (FVC) was 1.5 ± 0.5 l equal to 42 ± 10% of predicted. Mean PaCO~2~ was 53 ± 5 mmHg. Mean 6-min walking distance was 203 ± 97 m. Characteristics of patients at baseline are summarized in [Table 1](#table1-1753465816676222){ref-type="table"}.

###### 

Characteristics of patients at baseline.

![](10.1177_1753465816676222-table1)

  Characteristic                          Values
  --------------------------------------- -------------
  Number of patients                      10
  Age, years                              64 ± 9
  Sex                                     
   Female                                 7 (70.0%)
   Male                                   3 (30.0%)
  Distribution of emphysema               
   Homogeneous                            8 (80.0%)
   Heterogeneous                          2 (20.0%)
  Treatment for lung disease              
   β~2~-agonist                           10 (100.0%)
   Anticholinergic                        10 (100.0%)
   Inhaled corticosteroid                 8 (80.0%)
   Systemic corticosteroid                1 (10.0%)
   Theophylline                           4 (40.0%)
   Roflumilast                            2 (20.0%)
   Acetylcysteine                         2 (20.0%)
   Long-term oxygen therapy               10 (100.0%)
   Intermittent noninvasive ventilation   7 (70.0%)
  Blood gas analysis                      
   PaCO~2~ (mmHg)                         53 ± 5
   Base excess (mmol/l)                   7.2 ± 2.7
   HCO~3~^-^ (mmol/l)                     32.9 ± 2.8
   pH                                     7.42 ± 0.04
  Pulmonary function                      
   FEV~1~/FVC (%)                         32 ± 5
   FEV~1~ (l)                             0.5 ± 0.1
   FEV~1~ (% of predicted)                17 ± 5
   FVC (l)                                1.5 ± 0.5
   FVC (% of predicted)                   42 ± 10
   TLC (l)                                7.6 ± 1.1
   TLC (% of predicted)                   130 ± 14
   RV (l)                                 6.1 ± 0.9
   RV (% of predicted)                    280 ± 48
   RV/TLC (%)                             81 ± 5
   Raw~tot~ (kPa•s/l)                     1.8 ± 0.6
   sRaw~tot~ (kPa•s)                      11.6 ± 4.6
   TLCO (ml/min/kPa)                      0.7 ± 0.3
   TLCO (% of predicted)                  8.6 ± 3.6
  6-min walk test (m)                     203 ± 97

Values are given as mean and standard deviation or as absolute numbers and percentages.

FEV~1~, forced expired volume in one second; FVC, forced vital capacity; PaCO~2~, partial pressure of carbon dioxide in arterial blood; Raw~tot~, total airway resistance; RV, residual volume; sRaw~tot~, specific total airway resistance; TLC, total lung capacity; TLCO, transfer factor of the lung for carbon monoxide.

Characteristics of the LVRC procedure {#section16-1753465816676222}
-------------------------------------

As defined in the inclusion criteria, LVRC treatment was performed bilaterally in two sequential procedures in all patients. The median interval between the two procedures was 84 days. In 90% of procedures one of the upper lobes was treated. A median number of 10 coils (range, 8--10) were placed per procedure. The mean length of hospital stay after the procedure was 6.8 ± 1.4 days. Characteristics of the LVRC procedure are shown in [Table 2](#table2-1753465816676222){ref-type="table"}.

###### 

Characteristics of the LVRC procedures.

![](10.1177_1753465816676222-table2)

                           First treatment     Second treatment
  ------------------------ ------------------- -------------------
  Number of procedures     10                  10
  Treated lobe                                 
   Right upper lobe        6 (60%)             3 (30%)
   Left upper lobe         3 (30%)             6 (60%)
   Right lower lobe        1 (10%)             1 (10%)
  Coils                                        
   Total number of coils   10 (range, 8--10)   10 (range, 9--10)
   Coil size 100 mm        8 (range, 4--10)    6 (range, 1--10)
   Coil size 125 mm        8 (range, 2--5)     4 (range, 2-- 9)
   Coil size 150 mm        1 (range, 1--3)     2 (range, 1-- 2)

Values are given as absolute numbers and percentages or as median and range.

LVRC, endoscopic lung volume reduction coil.

Adverse events {#section17-1753465816676222}
--------------

There were no adverse events during bronchoscopy or related to general anesthesia used for the procedure. Mild self-limiting hemoptysis occurred in the first days after 15 LVRC procedures (75%), of which 8 were first procedures and 7 were second procedures. In one case, hemoptysis required readmission to hospital and bronchial artery embolization to stop the bleeding and was therefore classified as a severe adverse event. Exacerbations of COPD within 4 weeks of LVRC treatment occurred after six procedures (30.0%). Of these, three were first procedures and three were second procedures in different patients. Apart from the one case of hemoptysis that was classified as a severe adverse event, all other adverse events resolved spontaneously or with routine medical care. There were no deaths.

Outcome {#section18-1753465816676222}
-------

Compared with baseline, after bilateral LVRC treatment, there was a significant increase in mean FEV~1~ of 19.1% from 0.5 ± 0.1 l to 0.6 ± 0.2 l (*p* = 0.004), a significant decrease in mean RV of 8.5% from 6.1 ± 0.9 l to 5.6 ± 1.1 l (*p* = 0.02) and a significant increase in mean FVC of 16.9% from 1.5 ± 0.5 l to 1.7 ± 0.4 l (*p* = 0.04). Changes in lung function are shown in [Figure 2](#fig2-1753465816676222){ref-type="fig"}. Mean 6-min walk distance increased by 20.1% from 203 ± 97 m to 244 ± 104 m (*p* = 0.22). An illustration of the changes in 6-min walk distance is provided in [Figure 3](#fig3-1753465816676222){ref-type="fig"}. Mean PaCO~2~ decreased significantly by 8.6% from 53 ± 5 mmHg to 48 ± 4 mmHg (*p* = 0.03). Changes in PaCO~2~ are shown in [Figure 4](#fig4-1753465816676222){ref-type="fig"}. Of the three patients in whom LVRC treatment was performed as a bridge to lung transplantation, two patients underwent lung transplantation during the follow-up period.

![Changes in lung function. Lung function at baseline, after unilateral LVRC treatment and after bilateral LVRC treatment.\
FEV~1~, forced expired volume in one second; FVC, forced vital capacity; LVRC, endoscopic lung volume reduction coil; RV, residual volume.](10.1177_1753465816676222-fig2){#fig2-1753465816676222}

![Changes in exercise capacity. Showing 6-min walk distance at baseline, after unilateral LVRC treatment and after bilateral LVRC treatment.\
LVRC, endoscopic lung volume reduction coil; 6-MWT, 6-minute walk test.](10.1177_1753465816676222-fig3){#fig3-1753465816676222}

![Changes in PaCO~2~. PaCO~2~ at baseline, after unilateral LVRC treatment and after bilateral LVRC treatment.\
LVRC, endoscopic lung volume reduction coil; PaCO~2~, partial pressure of carbon dioxide in arterial blood.](10.1177_1753465816676222-fig4){#fig4-1753465816676222}

Discussion {#section19-1753465816676222}
==========

In this retrospective observational study, we analyzed 10 patients with nonsevere chronic hypercapnic respiratory failure defined as a PaCO~2~ between 45--65 mmHg due to emphysema in whom bilateral endoscopic LVRC treatment was performed. LVRC treatment was found to be effective and safe in this group of patients. After LVRC treatment, we observed not only an improvement in lung function but also a reduction of hypercapnia.

LVRC treatment has been shown to improve lung function, exercise capacity and quality of life in patients with emphysema \[[@bibr7-1753465816676222]; [@bibr15-1753465816676222]; [@bibr32-1753465816676222]; [@bibr33-1753465816676222]\]. The recently published REVOLENS trial is the largest randomized trial on LVRC treatment published to date including 100 patients. In the 50 patients randomized to receive LVRC treatment, 6 months after the procedure, the authors found improvements in lung function with an increase in FEV~1~ of 9%, a decrease in RV of 9% and an increase in FVC of 15% as well as an improvement in 6-minute walk distance of 9% and improved quality of life \[[@bibr8-1753465816676222]\]. In our study, after LVRC treatment in patients with chronic hypercapnic respiratory failure, we observed similar ameliorations of lung function with an increase in mean FEV~1~ of 19.1%, a decrease in mean RV of 8.5% and an increase in mean FVC of 16.9%.

Chronic hypercapnic respiratory failure puts the patient at an increased periprocedural risk of death especially should complications arise. Indeed, hypercapnia has been reported to increase mortality associated with lung volume reduction surgery \[[@bibr23-1753465816676222]\]. LVRC treatment has been shown to have a good safety profile \[[@bibr12-1753465816676222]; [@bibr31-1753465816676222]\]. The REVOLENS trial reported 17 severe adverse events within 1 month of the procedure (4 chronic obstructive pulmonary disease exacerbations, 3 pneumothoraces, 1 case of hemoptysis, 1 case of thoracic pain, 5 cases of pneumonia, 1 cardiovascular event and 2 others) as well as 1 death which was however due to peritonitis \[[@bibr8-1753465816676222]\]. LVRC in patients with chronic hypercapnic respiratory failure in our study was shown to have an acceptable safety profile with only one serious adverse event, being hemoptysis, requiring readmission to hospital and bronchial artery embolization to stop the bleeding.

Chronic hypercapnic respiratory failure has been shown to be associated with poor prognosis. A prospective study by Yang and colleagues including 275 patients with COPD showed a median survival of 5.0 years in patients with hypercapnia compared with 6.5 years in patients with normocapnia (*p* = 0.016) \[[@bibr42-1753465816676222]\]. Therapeutic measures providing ventilatory support and thereby reducing hypercapnia have been shown to be beneficial in patients with chronic hypercapnic respiratory failure \[[@bibr28-1753465816676222]\]. In particular, the use of intermittent noninvasive positive-pressure ventilation has been thoroughly investigated. In a randomized controlled trial, Köhnlein and colleagues observed that the addition of long-term noninvasive pressure ventilation to standard treatment improved survival in patients with chronic hypercapnic respiratory failure when noninvasive ventilation was targeted to reduce hypercapnia \[[@bibr17-1753465816676222]\]. Budweiser and colleagues observed a significant weight gain in cachectic patients with COPD and chronic hypercapnic respiratory failure receiving noninvasive ventilation \[[@bibr5-1753465816676222]\]. The question of whether or not an improvement of prognosis or nutritional status may also be achieved by other measures leading to the reduction of hypercapnia by decreasing ventilatory workload like lung volume reduction remains to be investigated. However, the concept appears promising in theory.

Concerning lung volume reduction surgery, there has been much debate on the effects and risks of the procedure in patients with chronic hypercapnic respiratory failure and on whether or not the procedure should be performed in patients with hypercapnia at all. However, the data available suggest that lung volume reduction surgery is capable of improving gas exchange, lung function and quality of life while exhibiting an acceptable safety profile in patients with chronic hypercapnic respiratory failure. The national emphysema treatment trial included patients with a PaCO~2~ of up to 60 mmHg \[[@bibr10-1753465816676222]\]. Although hypercapnia was found to increase the mortality rate associated with lung volume reduction surgery, it did not clearly identify patients for whom surgery posed a substantially higher risk than medical treatment \[[@bibr23-1753465816676222]\]. Other studies on lung volume reduction surgery \[[@bibr2-1753465816676222]; [@bibr1-1753465816676222]; [@bibr41-1753465816676222]; [@bibr24-1753465816676222]; [@bibr30-1753465816676222]; [@bibr37-1753465816676222]; [@bibr22-1753465816676222]\] analyzing patients with hypercapnic respiratory failure showed improvements of hypercapnia, pulmonary function, exercise capacity, dyspnea and quality of life. The studies are summarized in [Table 3](#table3-1753465816676222){ref-type="table"}. Shade and colleagues found the degree of decrease in PaCO~2~ after lung volume reduction surgery in patients with moderate hypercapnia to be dependent on the baseline level of PaCO~2~ with the greatest reduction in PaCO~2~ seen in patients with higher baseline levels of PaCO~2~ \[[@bibr30-1753465816676222]\].

###### 

Studies on lung volume reduction surgery in patients with hypercapnic respiratory failure.

![](10.1177_1753465816676222-table3)

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                        Number of patients with HRF   Severity of HRF (PaCO~2~)   Outcome
  ---------------------------- ----------------------------- --------------------------- ---------------------------------------------------------------
  [@bibr2-1753465816676222]    9                             \>55 mmHg                   Improvement in pulmonary function.\
                                                                                         Improvement in exercise capacity.\
                                                                                         Improvement in dyspnea.

  [@bibr1-1753465816676222]    12                            \>45 mmHg                   Decrease in PaCO~2~ from 53 ± 6 mmHg to 47 ± 5 mmHg.

  [@bibr41-1753465816676222]   22                            ⩾45 mmHg                    Decrease in PaCO~2~ from 51.7 ± 1.7 mmHg to 41.3 ± 1.7 mmHg.

  [@bibr24-1753465816676222]   15                            \>45 mmHg                   Decrease in PaCO~2~ from 59 ± 7 mmHg to 50 ± 9 mmHg.\
                                                                                         Improvement in pulmonary function.\
                                                                                         Improvement in exercise capacity.\
                                                                                         Improvement in quality of life.

  [@bibr30-1753465816676222]   33                                                        Decrease in PaCO~2~ from 44 ± 7 mmHg to 42 ± 5 mmHg.\
                                                                                         Improvement in pulmonary function.

  [@bibr37-1753465816676222]   3                             \>50 mmHg                   Decrease in PaCO~2~ from 52 ± 1 mmHg to 48 ± 2 mmHg.

  [@bibr22-1753465816676222]   6                             ⩾60 mmHg                    Decrease in PaCO~2~ from 70.4 ± 9.4 mmHg to 46.9 ± 3.4 mmHg.\
                                                                                         Improvement in pulmonary function.
  ------------------------------------------------------------------------------------------------------------------------------------------------------

HRF, hypercapnic respiratory failure; PaCO~2~, partial pressure of carbon dioxide in arterial blood.

At present, the evidence for bronchoscopic lung volume reduction in patients with respiratory failure is limited to anecdotal data about the use of occlusive devices in patients with bullous emphysema and acute ventilatory failure requiring mechanical ventilation. Tsujino and colleagues described the use of endobronchial silicone spigots in a patient with acute respiratory failure and bullous emphysema whose respiratory condition improved after endoscopic lung volume reduction \[[@bibr36-1753465816676222]\]. Sexton and colleagues, Votruba and colleagues and Bierach and colleagues each reported cases of a patient with acute respiratory failure and bullous emphysema who could be liberated from mechanical ventilation after endoscopic lung volume reduction using endobronchial valves \[[@bibr29-1753465816676222]; [@bibr39-1753465816676222]; [@bibr4-1753465816676222]\].

To our knowledge, to date there is no study on the effects of endoscopic lung volume reduction in patients with chronic hypercapnic respiratory failure. In this analysis on LVRC treatment in patients with chronic hypercapnic respiratory failure, mean PaCO~2~ was seen to decrease significantly from 53 ± 5 mmHg to 48 ± 4 mmHg (*p* = 0.03) after LVRC treatment.

In this study, only patients were included in whom bilateral LVRC treatment was performed. While LVRC treatment has traditionally been a primarily bilateral approach and data for bilateral lung volume reduction surgery is also available, for one-way valves, data predominantly rely on unilateral procedures. Recently, a study on sequential bilateral bronchoscopic lung volume reduction with one-way valves has been published showing improvements in respiratory function in patients with bilateral heterogeneous emphysema \[[@bibr9-1753465816676222]\]. The question of whether endoscopic lung volume reduction should be primarily planned as a unilateral or as a bilateral approach and what the criteria should be to continue with contralateral treatment in cases where a primarily unilateral approach was chosen cannot be definitively answered to date. An individualized approach being tailored to the characteristics of patient and emphysema, taking into consideration the changes in physiological parameters resulting after the first procedure and possibly involving hybrid procedures incorporating different techniques of lung volume reduction might be expected.

The study has some methodological limitations. The interpretation of the results is limited by potential biases introduced by the retrospective study design and the small number of patients. However, the outcome and safety profile of LVRC treatment in this selected and highly vulnerable subgroup of patients with emphysema were comparable with the overall results of previously published studies on LVRC treatment. LVRC treatment was additionally shown to be capable of reducing ventilatory workload leading to the improvement of hypercapnia. Thus, patients with chronic hypercapnic respiratory failure should probably not be excluded from further evaluation for LVRC treatment solely for the presence of hypercapnia. Prospective studies including more patients are now needed to further assess the value of LVRC treatment in patients with chronic hypercapnic respiratory failure.

Conclusion {#section20-1753465816676222}
==========

LVRC treatment could be performed safely in patients with nonsevere chronic hypercapnic respiratory failure. It led not only to an improvement in lung function but also to an improvement of hypercapnia. Thus, patients with chronic hypercapnic respiratory failure should probably not be excluded from further evaluation for LVRC treatment solely for the presence of hypercapnia.
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